Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
EXELIXIS, INC. director Mary C. Beckerle reported an exercise-and-sell transaction in company stock. She sold 7,712 shares of common stock in an open-market sale at $48.45 per share. She also exercised options to acquire 3,856 shares at an exercise price of $23.24 per share. Following these transactions, she holds 25,236 shares of common stock, including 17,524 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Maria C. Freire reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised options to acquire 20,634 shares of Common Stock at $19.77 per share, then sold 20,634 shares in an open-market sale at $46.00 per share.
After these transactions, she directly holds 100,819 shares of Common Stock, which include 9,812 shares that will be issued upon vesting of restricted stock units. The option exercised covered 20,634 shares, became fully exercisable on May 23, 2019, and now has no remaining balance.
EXELIXIS, INC. director George Poste reported an open-market sale of 60,000 shares of common stock on May 7, 2026 at a weighted average price of $45.71 per share. The transactions were executed in multiple trades between $45.65 and $45.85 per share.
Following the sale, Poste directly holds 118,832 shares of Exelixis common stock, which includes 9,812 shares that will be issued upon vesting of restricted stock units (RSUs). Each RSU represents the economic equivalent of one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported a charitable stock transfer and updated holdings. On May 6, 2026, he made a bona fide gift of 109,676 shares of Exelixis common stock to the Bombora Rise Foundation through the Morrissey Family Living Trust, which then held 1,880,280 shares indirectly. He is also shown with 1,614,552 shares of common stock that will be issued upon vesting of restricted stock units and performance-based awards, plus 17,728 shares held through the Exelixis 401(k) Plan.
EXEL filed a Form 144 notice reporting proposed transactions in Common stock tied to compensation activity. The filing lists 3,856 shares related to restricted stock vesting on 01/05/2026 and 3,856 shares from option exercises on 05/07/2026, with trades to be handled through Morgan Stanley Smith Barney LLC on NASDAQ.
EXEL reported a notice of proposed sale of securities: the filing lists a proposed sale of 60,000 shares of Common Stock and an aggregate amount of $2,742,468.00, with 251,355,083 shares shown on the same line and the date 05/07/2026. The schedule itemizes multiple tranches of restricted stock vesting under a registered plan with specific vesting dates and share counts (examples: 3,457; 3,458; 15,538). The notice is a routine Form 144 disclosure by an affiliate identifying securities to be sold under a registered plan.
Exelixis, Inc. reported strong first‑quarter 2026 growth, driven mainly by its cabozantinib franchise. Total revenues rose to $610.8 million from $555.4 million a year earlier, with net product revenues increasing to $555.0 million. Net income climbed to $210.5 million, up from $159.6 million, and diluted EPS improved to $0.79 from $0.55, reflecting operating leverage as total operating expenses stayed roughly flat.
The company ended the quarter with $1.43 billion in cash, cash equivalents and marketable securities and continued returning capital to shareholders, repurchasing common stock for $430.4 million of cash in the quarter as part of a broader buyback program. Exelixis also highlighted progress in its oncology pipeline, including zanzalintinib, which has an FDA‑accepted New Drug Application in metastatic colorectal cancer and multiple ongoing pivotal and phase 2 studies across several tumor types.
Exelixis reported strong first quarter 2026 results and expanded its stock repurchase plans. Total revenues were $610.8 million, up from $555.4 million a year earlier, driven by net product revenues of $555.0 million, largely from the U.S. cabozantinib franchise. GAAP net income was $210.5 million, or $0.79 per diluted share, while non-GAAP diluted EPS was $0.87.
The company reaffirmed 2026 guidance, including total revenues of $2.525–$2.625 billion and net product revenues of $2.325–$2.425 billion, with an effective tax rate of 21–23%. Exelixis’ board authorized a new $750 million stock repurchase program through December 31, 2027, after repurchasing $590.6 million under its October 2025 program and $2.59 billion cumulatively since March 2023, retiring 86.8 million shares.
Pipeline momentum continued as the FDA accepted the NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Multiple pivotal trials, including STELLAR-303, STELLAR-304, STELLAR-311, STELLAR-316 and Merck’s LITESPARK-033 and -034, are underway or planned across colorectal, renal cell, neuroendocrine and other tumors.
Exelixis Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 13,233,247 shares of common stock, representing 5.09% of the class. The filing states Vanguard has sole dispositive power over 13,233,247 shares and sole voting power over 1,974,263 shares.
The filing lists Vanguard affiliates and clarifies holdings include shares held for funds and managed accounts. The form is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.